IRIS
BELLI, Carmen
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.979
NA - Nord America 990
EU - Europa 464
SA - Sud America 447
AF - Africa 65
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 2
Totale 3.954
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 927
SG - Singapore 765
CN - Cina 390
BR - Brasile 318
VN - Vietnam 299
IT - Italia 196
HK - Hong Kong 168
BD - Bangladesh 71
FR - Francia 61
KR - Corea 54
DE - Germania 49
IN - India 48
AR - Argentina 47
FI - Finlandia 44
IQ - Iraq 30
NL - Olanda 29
ZA - Sudafrica 23
EC - Ecuador 18
GB - Regno Unito 18
RU - Federazione Russa 17
CA - Canada 16
MX - Messico 16
MY - Malesia 16
TR - Turchia 16
VE - Venezuela 16
CO - Colombia 14
ID - Indonesia 14
PK - Pakistan 14
UZ - Uzbekistan 14
PL - Polonia 13
CL - Cile 12
KE - Kenya 10
NP - Nepal 10
PY - Paraguay 10
MA - Marocco 9
JO - Giordania 8
LT - Lituania 7
SA - Arabia Saudita 7
UA - Ucraina 7
AZ - Azerbaigian 6
PH - Filippine 6
AU - Australia 5
DO - Repubblica Dominicana 5
GE - Georgia 5
KZ - Kazakistan 5
PE - Perù 5
TT - Trinidad e Tobago 5
UY - Uruguay 5
CI - Costa d'Avorio 4
CR - Costa Rica 4
ES - Italia 4
GT - Guatemala 4
IL - Israele 4
JP - Giappone 4
ET - Etiopia 3
HN - Honduras 3
IE - Irlanda 3
JM - Giamaica 3
OM - Oman 3
RS - Serbia 3
SN - Senegal 3
SY - Repubblica araba siriana 3
AE - Emirati Arabi Uniti 2
BH - Bahrain 2
BO - Bolivia 2
DZ - Algeria 2
EG - Egitto 2
IR - Iran 2
KG - Kirghizistan 2
LB - Libano 2
NI - Nicaragua 2
PA - Panama 2
PT - Portogallo 2
TN - Tunisia 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AL - Albania 1
AM - Armenia 1
BB - Barbados 1
BE - Belgio 1
BG - Bulgaria 1
BW - Botswana 1
CG - Congo 1
CH - Svizzera 1
CM - Camerun 1
GH - Ghana 1
GR - Grecia 1
HU - Ungheria 1
KH - Cambogia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
MD - Moldavia 1
MK - Macedonia 1
MZ - Mozambico 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PF - Polinesia Francese 1
QA - Qatar 1
RW - Ruanda 1
Totale 3.948
Salva come PNG Salva come JPEG
Città #
Singapore 306
San Jose 188
Hong Kong 165
Council Bluffs 146
Boardman 106
Ho Chi Minh City 106
Ashburn 89
Hefei 81
Beijing 80
Hanoi 66
Seoul 53
Florence 49
Lauterbourg 45
Shanghai 43
Helsinki 39
Dallas 37
Phoenix 30
Milan 28
Santa Clara 23
São Paulo 23
Haiphong 22
Munich 21
Ogden 21
New York 18
Los Angeles 17
Falkenstein 16
Amsterdam 15
Rome 15
Rio de Janeiro 13
Tashkent 13
Baghdad 12
Da Nang 12
Warsaw 12
Biên Hòa 10
Frankfurt am Main 9
Kuala Lumpur 9
Belo Horizonte 8
Johannesburg 8
The Dalles 8
Amman 7
Caracas 7
Lahore 7
Campinas 6
Dhaka 6
Guayaquil 6
Istanbul 6
London 6
Nairobi 6
Asunción 5
Baku 5
Bologna 5
Brasília 5
Cape Town 5
Chennai 5
Chicago 5
Goiânia 5
Hải Dương 5
Lappeenranta 5
Lima 5
Montevideo 5
Moscow 5
Mumbai 5
New Delhi 5
Omaha 5
Quito 5
Abidjan 4
Brooklyn 4
Buenos Aires 4
Buffalo 4
Curitiba 4
Diadema 4
Gorle 4
Guarulhos 4
Guatemala City 4
Kilburn 4
Manchester 4
Mexico City 4
Ninh Bình 4
Orem 4
Osasco 4
Paola 4
Pittsburgh 4
Bauru 3
Belgrade 3
Blumenau 3
Boston 3
Can Tho 3
Cotia 3
Dakar 3
Denver 3
Erbil 3
Guangzhou 3
Hillsboro 3
Jeddah 3
Johor Bahru 3
Joinville 3
Mauá 3
Melbourne 3
Naples 3
Nha Trang 3
Totale 2.226
Salva come PNG Salva come JPEG
Nome #
Variant allele frequency: a decision-making tool in precision oncology? 156
Expression of the oncoproteins p16, p53 and Ki67 as predictive value in the differentiation of low-grade intracervical neoplasms of high and low risk 132
Malignant pleural mesothelioma: Current treatments and emerging drugs 120
Development and Validation of a Serum Metabolomic Signature for Endometrial Cancer Screening in Postmenopausal Women 118
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: Cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen) 109
ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research 106
Capecitabine with/without mitomycin C: Results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma 104
Safety of covid-19 mrna vaccines in patients with cancer enrolled in early-phase clinical trials 102
Breast metastases from oligodendroglioma: An unusual extraneural spread in two young women and a review of the literature 98
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden 93
Clinical significance of skin toxicity due to EGFR-targeted Therapies 92
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study) 86
Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents 86
Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer 82
(Ir)relevance of metformin treatment in patients with metastatic pancreatic cancer: An open-label, randomized phase II trial 81
Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer 81
Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trial 81
The Pan-Immune-Inflammation Value in microsatellite instability–high metastatic colorectal cancer patients treated with immune checkpoint inhibitors 81
Targeting the microenvironment in solid tumors 79
Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting 79
Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience 78
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents 76
Adjuvant treatment in biliary tract cancer: To treat or not to treat? 76
Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity 76
The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A review 73
Immunomodulatory agents with antivascular activity in the treatment of non-small cell lung cancer: Focus on TLR9 agonists, IMiDs and NGR-TNF 73
Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies 72
Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions 72
A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data 70
Homologous recombination deficiency in triple negative breast cancer 67
Will antiangiogenic agents be a future for mesothelioma therapy? 66
Liver toxicity in the era of immune checkpoint inhibitors: A practical approach 66
The emerging role of PI3K inhibitors for solid tumour treatment and beyond 65
Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: Not just a case? 65
Antiangiogenic strategies in breast cancer management 65
Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors 63
Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population 61
Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience 61
XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer 58
Neoadjuvant therapy in resectable pancreatic cancer: A critical review 56
Progresses toward precision medicine in RET-altered solid tumors 56
The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046 54
Translational therapies for malignant pleural mesothelioma 53
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer 53
Role of taxanes in pancreatic cancer 52
Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma 52
Mesoteliona Pleurico 50
Tumori del polmone 50
Second-line therapy in advanced biliary tract cancer: What should be the standard? 49
Neo-adjuvant and adjuvant chemotherapy of gastric cancer 48
Malignant Mesothelioma 48
Unity is strength: One, two, or more drugs against advanced pancreatic cancer? 46
Mesotelioma Pleurico 29
Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations 21
Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials 16
Deleterious alterations in homologous recombination repair genes and efficacy of platinum-based chemotherapy in biliary tract cancers 16
The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit 15
Unfavorable carcinoma of unknown primary with a gastrointestinal profile: a retrospective study 13
Interstitial lung disease in patients enrolled in early-phase clinical trials: the ILDE study 13
Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology 11
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis 11
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer 9
Peritoneal effusion: an uncommon adverse effect of selective RET inhibitors 7
Totale 4.097
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.932
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.932
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/2023194 0 0 0 0 0 0 0 0 140 5 49 0
2023/2024200 5 1 27 8 15 6 8 32 35 13 14 36
2024/20251.006 36 114 23 42 47 106 15 70 155 31 85 282
2025/20262.597 325 116 105 200 507 147 306 169 169 213 137 203
2026/2027100 100 0 0 0 0 0 0 0 0 0 0 0
Totale 4.097